WESTMONT, IL--(Marketwire - May 22, 2008) - TMD and DxS will sponsor a symposium on the profiling of solid tumor mutations for the purpose of directing targeted therapy at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on June 1, 2008. The company will host presentations and comments from industry leaders that will include: Dr. Roy Herbst (MD Anderson), Dr. Pasi Janne (Harvard Medical), Dr. David Sidransky (Johns Hopkins University), Dr. David Solit (Memorial Sloan-Kettering Cancer Center), and Prof. Sabine Tejpar (University Hospital Gasthuisberg). The experts will present recent findings on the use of solid tumor mutations to guide monoclonal antibody and small molecule inhibitor therapy on diseases such as colorectal and lung carcinoma.
